articleThe Lancet OncologyDec 19, 2015GREEN OA

Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial

ATAlice T. ShawLGLeena GandhiSMShirish M. GadgeelGJGregory J. RielyJCJeremy Cetnar

Massachusetts General Hospital · Dana-Farber Cancer Institute · +13 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

637
total citations
FWCI
78.34
Percentile
100%
References
28
Citations per year

Authors

19

Topics & keywords

Topics
Keywords
  • Alectinib
  • Crizotinib
  • Medicine
  • Lung cancer
  • Internal medicine
  • Oncology
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding